How does Apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model

doi:10.21203/rs.3.rs-1753069/v1

Download PDF

Systematic Review

How does Apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model

https://doi.org/10.21203/rs.3.rs-1753069/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 27 Jan, 2023

Read the published version in Alzheimer's Research & Therapy →

You are reading this latest preprint version

Background: Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD). On the other hand, the Apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor for developing AD. Extensive research has been conducted to determine whether frequent PA can mitigate the increased AD risk associated with APOE ε4. However, thus far these attempts have produced inconclusive results. In this context, one possible explanation could be that the influence of the combined effect of PA and APOE ε4 carriage might be dependent on the specific outcome measure utilized.

Main body: In order to bridge these discrepancies, the aim of this theoretical article is to propose a novel model on the interactive effects of PA and APOE ε4 carriage on well-established mechanisms underlying AD. Available literature was searched to investigate how PA and APOE ε4 carriage, independently and in combination, may alter several molecular pathways involved in AD pathogenesis. The reviewed mechanisms include amyloid beta (Aβ) and tau deposition and clearance, neuronal resilience and neurogenesis, lipid function and cerebrovascular alterations, brain immune response and glucose metabolism. Finally, combining all this information we have built an integrative model, which includes evidence-based and theoretical synergistic interactions across mechanisms. Moreover, we have identified key knowledge gaps in the literature, providing a list of testable hypotheses that future studies need to address.

Conclusions: We conclude that PA influences a wide array of molecular targets involved in AD neuropathology. A deeper understanding of where, when and, most importantly, how PA decreases AD risk even in the presence of the APOE ε4 allele will enable the creation of new protocols using exercise along pharmaceuticals in combined therapeutic approaches.

APOE ε4

Alzheimer’s disease

physical activity

amyloid pathology

tau pathology

cerebrovascular health

neurotrophic factors

neuroinflammation

glucose metabolism

mitochondrial dysfunction.

Physical activity (PA) and APOE ε4 contribute to AD risk in opposite directions.
The combined effect of PA and APOE ε4 varies across several mechanisms in AD.
We propose an integrative model of how PA might partially offset APOE ε4 damage.
This integrative model could aid to formulate new combined therapeutic strategies.

Physical activity (PA) engagement is one of the most effective methods for reducing the risk of multiple diseases, including cancer, dementia and cardiovascular disease(1). Additionally, PA engagement has neural benefits, slowing neuropathological processes associated with Alzheimer’s disease (AD).

Numerous modifiable and non-modifiable elements contribute to increased AD risk. One of the most relevant non-modifiable factors that contributes to AD risk is the carriage of the Apolipoprotein E (APOE) ε4 gene allele. The APOE ε4 allele is present in 60–80% of AD cases and increases AD risk in a dose-dependent manner(2). The number of ε4 alleles has also been found to be negatively associated with age at onset(3). Apolipoprotein E (ApoE – protein) is the most abundant apolipoprotein in the brain, where it plays a fundamental role in cholesterol and lipid transport and metabolism. The APOE polymorphisms can substantially change the structure and function of the protein, modifying its binding properties. In a recent publication, Flowers & Rebeck(4) have summarized the main differences in structure and neural effects between the three most common isoforms. According to the authors, the degree of lipidation of the three common ApoE isoforms varies, where ApoE2 is associated with more lipidated particles and ApoE4 with less lipidated particles than ApoE3 (ApoE2 > ApoE3 > ApoE4). The level of lipidation of ApoE affects the efficiency of lipid transport and receptor-binding interaction. ApoE4 binding to high-density lipoproteins (HDL) is lower compared with other isoforms, which makes the aggregation of unlipidated ApoE monomers more likely. These large aggregates are more toxic to neurons than those formed by ApoE2 and ApoE3.

In this scenario, one relevant question emerges: Does APOE genotype influence the relationship between PA and AD risk? In other words, can a modifiable factor (i.e., PA) mitigate some of the risk of a non-modifiable factor (APOE ε4 carriage)? Over the last two decades, scientists have attempted to answer this question, yielding vastly inconsistent results(5, 6). In a recent systematic review, we identified, along with multiple methodological issues, one critical consideration that could partially explain the lack of convergent results within this field: The influence of the combined effect of PA and APOE ε4 carriage might be dependent on the specific outcome measure used. Studies examining various AD-related traits (e.g., amyloid beta burden or cortical atrophy) might show diverse results because the biological pathways involved are differentially influenced by PA, APOE ε4 carriage and their interaction.

The aim of this theoretical article is to propose a novel model of how PA and APOE ε4 carriage, independently and in combination, may alter well-established mechanisms underlying AD pathogenesis. The reviewed mechanisms include amyloid beta (Aβ) and tau deposition and clearance, neuronal resilience and neurogenesis, lipid function and cerebrovascular alterations, brain immune response, and glucose metabolism. Moreover, our integrative model includes evidence-based and theoretical synergistic interactions across mechanisms, as well as a proposal of testable hypotheses that future studies need to address. A better understanding of where, when and most importantly, how, PA decreases AD risk in the presence of the APOE ε4 allele is essential to formulate combined therapeutic approaches in the absence of a cure for AD.

2.1. Amyloid pathology

Aggregation of Aβ and the resultant plaque formation is one hallmark of AD, initiating a series of pathological cascades leading to neuronal death and cognitive decline(7). An intermediary of Aβ deposition, soluble Aβ oligomers, are the most neurotoxic aggregates and are associated with neural dysfunction, induce neuronal apoptosis, and inhibition of synaptic long-term potentiation (LTP)(8). Aβ oligomers contribute to the neurotoxic environment through receptor binding, mitochondrial dysfunction, and tau pathologies, resulting in declines in cognitive function(8). APOE ε4 carriers show increased levels of soluble Aβ compared to non-carriers, detailing the central role of apoE Aβ metabolism(9); and exercise has also been shown to reduce levels of soluble Aβ(10).

Evidence from animal studies indicates that both exercise and PA (forced and voluntary wheel running, respectively) are associated with lower levels of cortical Aβ(11, 12). Importantly, exercise may contribute to both reduced production and increased clearance of cortical Aβ. Facilitation of Aβ accumulation may occur via processing of amyloid precursor protein (APP), which is processed either via the non-amyloidogenic pathway (leads to neuronal growth and excitability) or amyloidogenic pathway (produces the building blocks for Aβ plaques)(13). Exercise can modulate enzymes which are involved in APP cleavage, such as ADAM-10(14), presenilin (PS1)(15), and BACE1(16), reducing APP cleavage via the amyloidogenic pathway, and thereby decreasing the production of Aβ(17) in mouse models of AD.

ApoE4 plays a central role in driving Aβ accumulation, through both facilitating Aβ aggregation and inhibiting Aβ clearance(18). For example, ApoE4 is less efficient at clearing soluble Aβ from the interstitial fluid (ISF), as opposed to ApoE2 or ApoE3(19). ApoE isoforms may also mediate the clearance of Aβ via the blood brain barrier (BBB), with ApoE4 being the least efficient(20). Indeed, a combination of chronically elevated IL-6 (a pro-inflammatory cytokine) and BBB dysfunction has been associated with greater Aβ in APOE ε4 carriers only(21). Additionally, ApoE4 binding to Aβ may alter the Aβ clearance pathway from the LDL receptor–related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalises Aβ-ApoE4 complexes at the BBB more slowly than LRP1(22). However, ApoE may also compete with Aβ for cellular uptake via LDLR receptors(23). It remains unclear whether ApoE facilitates cellular Aβ uptake via forming Aβ-ApoE4 complexes, whose clearance efficiency is ApoE isoform dependent, or whether ApoE may compete with Aβ for receptor binding(24). Finally, the ApoE4 isoform may be less efficient at promoting Aβ degradation via neprilysin (an Aβ degrading enzyme), compared to ApoE2 and ApoE3(25).

Current evidence from human research indicates PA-induced reductions in brain Aβ may be greater for APOE ε4 allele carriers, compared to ε4 non-carriers(6). Although this evidence is relatively consistent, there is very little research examining the potential mechanisms for this interaction. However, when investigated separately, ApoE and PA have shared mechanistic pathways to influence AD biomarkers, thus it is likely that there is an interaction between these factors on the molecular level. For example, ApoE may affect the clearance of soluble Aβ in the ISF in an isoform dependent manner (ApoE4 < ApoE3 ≤ ApoE2). However, exercise can accelerate the movement of ISF drainage fluids, accelerating Aβ clearance and reducing Aβ accumulation(26). Through this mechanistic pathway, PA may attenuate some of the negative impacts of the ε4 allele, which is consistent with studies which show greater exercise-induced benefit for ε4 carriers. Moreover, ApoE and exercise may both act to regulate proteases such as LRP1 and neprilysin to influence Aβ degradation and clearance. For example, PA may upregulate LRP1, leading to increased Aβ clearance(27) However, the effectiveness of this pathway may be ApoE isoform dependent, in that Aβ binding to ApoE4 alters the clearance pathway from LRP1 to VLDL, which is a less efficient clearance method(28). Thus, if ApoE4 is altering this clearance pathway, the exercise-induced increase in levels of LRP1 may be less effective for increasing Aβ degradation. Additionally, exercise has been shown to upregulate neprilysin and insulin-degrading enzyme (IDE), leading to increased Aβ degradation in animal models(27). Post-mortem studies show ε4 carriers have reduced expression of neprilysin and IDE in the brain, compared to ε4 non-carriers, and efficiency of Aβ degradation via neprilysin may be ApoE isoform dependent (ApoE4 being the least efficient)(25, 29, 30). Thus, exercise-induced increases in neprilysin and IDE may partially mitigate Aβ degradation inefficiency in ε4 carriers specifically. Figure 1 presents a summary of hypothesized associations between APOE gene allele carriage, physical activity, inflammatory factors and Aβ.

2.2. Tau pathology

Neurofibrillary tangles (NFTs) are a second hallmark of AD (additional to Aβ plaques) and are composed of hyperphosphorylated or abnormally phosphorylated tau aggregates(31). Importantly, tau aggregation is associated with clinical symptom onset and cognitive function in preclinical AD(32). Animal models of AD and other tauopathies show that exercise and PA can reduce hippocampal tau pathology and tau phosphorylation(33). Two main tau kinases (Glycogen synthase kinase 3; GSK3 and Cyclin-dependent kinase 5; CDK5), important for tau phosphorylation may be mechanisms through which PA reduces brain (hyper)phosphorylated tau(11). However, the mechanistic link between PA and tau is poorly understood, with one animal study showing that GSK3, but not CDK5, plays a mediating role in the relationship between exercise and tau phosphorylation, and other studies showing no effect of PA on various tau kinases(15, 33). Animal models suggest that upregulation of pro-inflammatory cytokines increases tau hyperphosphorylation, and higher PA levels in humans are associated with lower CSF tau and IL-8(34, 35).

ApoE4 increases tau hyperphosphorylation, however it is currently unclear whether this relationship is dependent on the presence of Aβ(36, 37). Indeed, a recent study showed that ApoE may facilitate tau phosphorylation induced by Aβ oligomers in an isoform-dependent manner, with ApoE4 being the most potent(38). Elevated CSF tau levels have been associated with decreased cortical plasticity and cognitive decline in APOE ε4, but not APOE ε3 carriers(39), supporting the notion that ApoE4 may enhance tau-mediated neurodegeneration(37).

There is very limited evidence for how ApoE and exercise may interact to influence tau pathology. However, a recent study(40) showed that overexpression of LDLR in tau transgenic mice reduces brain ApoE and attenuates tau pathology and neurodegeneration. As detailed above, PA may upregulate LDLR, thus indicating a potential mechanistic pathway through which PA and ApoE may interact to influence tau pathology, however, further research is required. Additionally, because the accumulation of tau pathology may be Aβ-dependent, future research should consider the role of Aβ in this process.

2.3. Neurotrophic factors

An integral component of PA-promoted neuroprotection is the proliferation of neurotrophins, which are a group of endogenous proteins critical for neuronal survival, regeneration and growth(41). In the context of AD, optimal neurotropic functioning might be key to counterbalancing structural damage through synaptic plasticity. Moreover, neurotrophic dysregulation has been reported early in the disease(42). Prominent families of neurotrophins include brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF) and vascular endothelial growth factor (VEGF). BDNF is found in high concentrations in the hippocampus and is integral to long-term potentiation, memory formation and synaptic function(43). Up-regulation of BDNF subsequently promotes neurogenesis, cell formation and leads to downstream cognitive benefits(44). Insulin-like growth factor 1 (IGF-1) is a growth hormone which is critical to cellular development (anabolism) and maintenance in the CNS, glucose metabolism and insulin regulation(45). VEGF is also a key promotor of hippocampal angiogenesis and microvasculature formation(46). Critically, animal studies have shown that increased IGF-1 expression via exercise also facilitates both blood vessel proliferation(47) and hippocampal neurogenesis(45).

A single bout of aerobic or resistance exercise can result in discernible increases in peripherally circulating BDNF (which is also a myokine), both in healthy older adults and those exhibiting cognitive decline(48–50). Studies of both voluntary and forced wheel running in rodents have found that aerobic exercise is effective in upregulating hippocampal BDNF, tropomyosin receptor kinase B (TrkB, a BDNF receptor) and VEGF concentrations(44, 51–53). Additionally, high-intensity exercise, which induces lactic acid build-up, appears to be most effective at stimulating VEGF hippocampal expression and angiogenesis(53). PA-induced increases in neurotrophic concentrations and the resulting neurogenesis can promote cognitive improvements and increases in hippocampal volume in humans(54). Moreover, serum IGF-1 concentration is promoted by resistance exercise, likely as a result of its anabolic action and role in muscle growth(55, 56).

The presence or absence of the APOE ε4 allele may play a key role in neurotrophic response to PA and exercise. Serum BDNF levels are lower in APOE ε4 AD participants compared to both non-APOE ε4 carriers diagnosed with AD and cognitively normal older adults(57, 58). Further, low serum BDNF could serve as a predictor of conversion from mild cognitive impairment (MCI) to AD in APOE ε4 carriers(59). The variations in BDNF secretion as a function of APOE status could occur via multiple pathways, including the direct inhibition of astrocytic expression of BDNF in ε4 carriers(60) and/or epigenetic repression of BDNF expression in neurons(60). Similarly, Keeney and colleagues(61) reported a novel association between APOE genotype and IGF-1, where transgenic mice modified to carry the human APOE ε4 allele had reduced cortical IGF-1 protein and hippocampal IGF-1 mRNA, compared to mice carrying the APOE ε2 allele. There was little difference in IGF-1 gene expression between ε4 and ε3 mice(61). Additionally, APOE ε4 transgenic mice had a reduced concentration of hippocampal VEGF compared to APOE ε3 animals(62).

The interaction between ApoE, PA and neurotrophic factors is likely complex and multi-faceted. Although APOE ε4 carriers benefit from PA engagement, ε4 carriage, especially in homozygotes, can diminish neurotrophic function(63), potentially through the detrimental effect of APOE ε4 allele on BDNF secretion and maturation. Exercise-induced BDNF could still support neurogenesis and synaptogenesis in APOE ε4 carriers, yet less effectively than in ε3 and ε2 carriers. Animal studies have shown that PA can increase levels of BDNF, its TrkB receptor (reduced by 50% in the presence of ε4 allele) and synaptophysin (a marker of synaptic function) in transgenic ε4 mice, to the level of ε3 mice (64). Accordingly, PA could mitigate some of the negative effects ε4 allele possession has on BDNF secretion. However, there is also evidence of increased neuronal apoptosis following voluntary wheel running in APOE ε4 mice, and increased neurogenesis in APOE ε3 mice (65). Although this study did not examine BDNF levels, it does indicate that PA-induced neurotrophic change and the resultant neuronal effects may be ApoE isoform-dependent.

The association between VEGF expression and APOE genotype is also poorly understood, owing to diverse findings in the peripheral and central expression of VEGF in AD samples compared with cognitively normal older adults(66). APOE ε4 transgenic mice have a reduced concentration of hippocampal VEGF compared to ε3 animals, while subsequent treatment with intra-hippocampal VEGF-A injections reversed aggregation of Aβ-42 and p-tau in APOE ε4 mice(62). Since there is evidence that exercise can stimulate hippocampal VEGF expression(53), it is plausible that PA may ameliorate some of the negative impacts ε4 carriage has on hippocampal VEGF and subsequent aggregation of Aβ-42 and p-tau. Higher expression of VEGF and a co-receptor (Neuropilin 1) have been associated with poorer cognitive performance in APOE ε4 carriers, while the inverse was true for non-carriers, suggesting any VEGF-derived neuroprotection was attenuated by possession of the ε4 allele(66). However, it remains unclear whether exercise-induced upregulation of VEGF may protect against cognitive decline or neurodegeneration in ε4 carriers. Further research assessing the neurotrophic response to exercise or longer-term PA patterns as a function of APOE genotype along with downstream effects on neurocognitive health is warranted. Figure 2 presents a summary of hypothesized associations between APOE gene allele carriage, physical activity and neurotrophic factors.

2.4. Cerebrovascular alterations

PA exerts a positive response in the cardiovascular system, which may also benefit the brain. Greater PA engagement is associated with increased cerebral blood flow and vascular perfusion, reduced resting pulse (which prevents microbleeds resulting from prolonged intense pulsatile stress on arteries), enhanced endothelial function and improved small vessel integrity(67–69). Several mechanisms have been proposed to underpin these protective effects, including increased endothelial progenitor cells and greater release and bioavailability of nitric oxide (a vasoactive substance essential for the vascular reactivity and the control of blood flow) by VEGF stimulation(70).

Conversely, lipid dysfunction, endothelial injury and vascular disease are risk factors for the development and progression of various types of dementia, including AD, where APOE ε4 carriage plays a major role. The conformation and lipidation state of ApoE isoforms affects their function, which includes the assembly, processing and removal of plasma lipoproteins. Lipoproteins assist with lipid transport and their normal functioning is key in the brain, given that lipids constitute majority of its dry mass. In this line, ApoE plays a major role in the transportation and homeostasis of cholesterol in the brain, binding lipids primarily through interactions with the ATP-binding cassette transporter 1 (ABCA1), forming HDL-like particles. Additionally, ApoE4, unlike ApoE3, interacts with triglyceride-rich lipoproteins, causing linear conformational changes in ApoE that alter its binding properties(71). Cell studies show that ApoE4 reduces astrocytes’ ability to export cholesterol, and mediates the reverse mechanism, the efflux of toxic peroxidated lipids from neurons to astrocytes for its clearance, which is key for neuroprotection at high levels of oxidative stress(72). ApoE4 also has a lower affinity for lipids compared to other ApoE isoforms, resulting in insufficient lipid availability for neuronal remodelling and repair processes. Altered synaptogenesis and neurogenesis due to depletion of lipid rafts causes a disruption of neural communication(73).

ApoE or its receptors are expressed in most cells participating in the formation, maintenance (e.g., astrocytes and endothelial cells), and interaction (e.g., macrophages and microglia) with, the BBB. Wide evidence (including a study using bioengineered human vessels) supports that ApoE4 compromises the integrity of the BBB, inducing degeneration of brain capillary pericytes and producing increased leakiness and deficient Aβ clearance through the BBB(74, 75). A leaky barrier makes the brain more susceptible to toxins and pathogens and increases the risk of neuronal dysfunction and neurodegeneration, including AD(73, 76). Moreover, BBB leakiness leads to a progressive accumulation of fatty molecules and macrophages causing atherosclerotic cerebrovascular disease, contributing to neurodegenerative processes(71, 73) such as AD. In this line, in humans CSF markers of BBB pericyte injury predict future cognitive decline only in APOE ε4 carriers(77). Ultimately, these cascades of events alter the integrity of the BBB, dysregulate cerebral blood flow, impair brain repair mechanisms and increase the risk of cerebral amyloid angiopathy. The alterations of cerebral blood flow are of particular interest, since hypoperfusion is a well-established feature of the AD human brain. However, blood flow modifications in APOE ε4 carriers seem to be non-linear and age- and region-dependent, where hyperperfusion is observed in cognitively normal ε4 carriers as a compensatory mechanism to meet the metabolic demands of hyperactive neuronal activity(75, 76, 78).

There is evidence that cerebrovascular adaptations following increased levels of PA might restore some, but not all, of the functions which are negatively affected by APOE ε4 carriage. For example, animal models show exercise prevents age-related decline in the integrity and function of the neurovascular unit in the frontoparietal cortex and the hippocampus, including greater preservation and coverage of pericytes(79). However, most of these positive effects were lost in ApoE-deficient (ApoE-/-) mice. In wild type mice, ApoE expression decreases with age, but can be preserved with exercise engagement. Like APOE knockout mice, APOE ε4 transgenic mice and human carriers also show lower brain levels of ApoE. Therefore, it seems that PA might not be sufficient to preserve neurovascular health in APOE ε4 carriers. Alternatively, greater levels of PA engagement than those registered by Soto et al. (2015)(79) might be required for carriers to show benefits. In this vein, ApoE-/- mice under a high cholesterol diet (an animal model of advanced atherosclerosis) did not show any benefits from PA, including no protective effects on BBB integrity(80). Still, in humans midlife PA has been shown to specifically reduce the risk of vascular dementia, independently of APOE genotype(81). Moreover, lower cerebral blood flow has been associated with higher physical fitness levels in a sample of healthy individuals where APOE ε4 carriers were reportedly over-represented, meaning that PA might be able to prevent the need for the activation of a potentially compensating mechanism(69). In fact, healthy APOE ε4 carriers show higher cerebral blood flow than non-carriers in the hippocampus as a function of longer sedentary time(82). Figure 3 presents a summary of hypothesized associations between APOE gene allele carriage, physical activity and cerebrovascular risk factors.

2.5. Neuroimmune response

Bouts of PA are associated with a transient increase in anti- and pro- inflammatory cytokines, such as IL-1, IL-10, IL-18, IL-1 receptor antagonist (IL-1ra), IL-6 and C reactive protein. However, while pro-inflammatory substances are released after exercising, physically fit individuals exhibit lower basal levels in comparison to their unfit and overweight counterparts, the latter of which tend to show a chronic state of low-level inflammation(83). As a result of the expansion of adipose tissue, the level of pro-inflammatory adipokines (e.g., TNF, IL-6, IL-18) increases, while the level of anti-inflammatory cytokines decreases. Exercise favours a reduction in abdominal and visceral fat, thus reducing the release of pro-inflammatory substances, and contributing to the increase in anti-inflammatory ones(84). PA also contributes to improved immune function through elevating levels of myokines, including IL-6 (one of the most effective immune regulators), proportional to exercise duration and intensity. The immunomodulatory role of IL-6 stems from its ability to stimulate the release of IL-10 and IL-1ra, and downregulate the release of TNF, promoting an anti-inflammatory state(85). Physical inactivity, systemic inflammation, and age-related diseases are associated with an upregulation of toll-like receptors (TLR), which have a key role in inflammation regulation through inducing the release of pro-inflammatory substances. PA has been shown to reduce the expression of these receptors (specifically, TLR2 and TLR4) both after acute and regular exercise bouts(84, 85). Finally, regular exercise contributes to lower baseline levels of pro-inflammatory monocytes and increased levels of circulating T regulatory cells(84).

The APOE genotype can modulate the innate immune response after an inflammatory stimulus, in animal models and humans, in vitro and in vivo. Specifically, ε4 allele carriage has been associated with increased immune reactivity. The ApoE4 protein is linked with a greater increment in number of microglia, astrocytes, and infiltrating T-cells, and enhanced secretion and longer-lasting elevations of cytokines such as IL-1B, TNF-a and NO(86–89). Additionally, APOE ε4 mice show basal structural and functional brain differences, including activated morphology of the microglia even in the absence of an inflammatory stimulus(87). Zhu et al.(89) found lower levels of PSD95 and debrin in APOE ε4 mice compared to APOE ε3 mice, which might be indicative of differences in basal postsynaptic densities across genotypes. These differences might arise from chronic inflammation, which could make the brain more susceptible to damage accumulation across time(89). Consequently, ApoE might behave as an anti-inflammatory agent, for example, the ApoE4 protein may be less efficacious than ApoE3 and ApoE2 at blocking inflammation(87, 89). Others, however, suggest that ApoE4 may promote neuroinflammation and neurodegeneration(88). In any case, the APOE ε4 allele has been consistently reported to increase the susceptibility to inflammation in a dose dependent-manner(86, 87).

The mechanisms through which ApoE4 contributes to the enhancement of inflammation are still being elucidated (see Fig. 1). Impairment or delay in the shift to the macrophage-orchestrated repair program could be one contributing factor (87). ApoE4 shows diminished ability to induce a cholesterol efflux from lipid rafts in comparison to ApoE3, which might result in a greater activation of TLRs, leading to higher levels of inflammatory cytokines(86, 90). Another proposed mechanism to explain the immunological influence of ApoE variants is through TREM2 binding, which may be key for microglia activation and interaction with Aβ plaques(90). ApoE4 is linked to higher microglial cell reactivity around Aβ plaques, compared to other isoforms, which may explain differences in plaque deposition(90). Finally, ApoE variants reduce the classical complement cascade (CCC) activation by binding to C1q, forming a complex found in Aβ plaques in both animal models and human brains(91). However, further research is needed to determine whether ApoE isoforms differentially reduce CCC activation, partially explaining the differential inflammatory responses evoked by each isoform.

Growing evidence suggests that the detrimental effects of the APOE ε4 allele carriage on cognitive performance, Aβ deposition and dementia risk could be mitigated or compensated by regular, moderate levels of PA(92, 93). Still, there is a striking lack of empirical evidence regarding the impact of the APOE ε4 genotype*PA interaction on the brain immune response. This is a promising field of research given that both ApoE and PA independently modulate key players of the immune system (e.g. IL-6, IL-10, TLRs).

2.6. Brain glucose metabolism

Cerebral glucose hypometabolism is commonly observed in AD; which has been referred to as brain-specific “diabetes mellitus type 3”(94). Glucose metabolism impairments can trigger vascular dysfunction in the brain, and such impairments are considered a modifiable causal factor, rather than a symptom of AD(95). In fact, there is epidemiological evidence that diabetes mellitus type 2 patients are at a higher risk of developing AD, and that effective treatment can reduce this risk(96).

Exercise can elicit a series of adaptations improving insulin signaling, glucose transport (mostly through GLUT4 translocation) and glucose metabolism in muscles(97, 98). Exercise engagement can improve peripheral insulin sensitivity both acutely and chronically, in insulin resistant patients and healthy individuals(97, 99). There is little research investigating insulin resistance and glucose metabolism within the CNS, however initial results are promising. For example, increases in cardiorespiratory fitness (not mere increases in PA engagement) after an exercise intervention in humans resulted in improved brain glucose metabolism(100). Animal models show that PA can reduce insulin resistance both in the periphery and in the brain(101, 102). Exercise can also enhance mitochondrial function in the hippocampus of mice with obesity-induced insulin resistance(103).

On the other hand, mice studies suggest that ApoE4 may impair insulin signaling and insulin-mediated mitochondrial respiration and glycolysis(104). Among memory-impaired older adults, only APOE ε4 non-carriers seem to benefit from nasal insulin administration in terms of improved memory performance(105). Cerebral glucose hypometabolism is a well-established marker of AD, which is exacerbated in APOE ε4 carriers in a region-specific(106, 107) and dose-dependent manner, compared to non-carriers(108). Furthermore, regional glucose metabolism has been identified as a risk factor for MCI in cognitively normal older adults(109) and glucose metabolism declines faster among APOE ε4 carrier MCI patients(110). Neurons have high energetic demands, relying heavily on glucose availability, which is mediated by glucose transporters. Reduced glycolytic flux and lower concentrations of glucose transporters (particularly GLUT3, the predominant brain isoform) are associated with AD severity in humans(111). Relevantly, lower levels of insulin receptors and transporters have been found in the brain of APOE ε4 gene-targeted replacement (TR) mice, and in APOE ε4 carrier AD patients compared to non-carriers, indicating hindered neuronal glucose uptake(112). APOE ε4 TR mice show lower levels of glucose transporters (mostly GLUT3), synthesize less hexokinase (an enzyme involved in glycolysis) and produce lower glycolytic outcomes as they age, leading to less efficient energy production in brain cells(113, 114). In mice, ApoE4 has also been linked to multiple markers of mitochondrial dysfunction, including lower protein levels of complexes I-V, reduced mitochondrial oxidative phosphorylation and energy metabolism and decreased ATP synthesis(115).

Unfortunately, there is a lack of empirical evidence on the combined effect of APOE ε4 carriage and PA on cerebral glucose metabolism. However, available data on each independent mechanism suggest that PA might counteract the detrimental effects of genetic risk.

In this section, we aim to propose a comprehensive overview of how the PA*APOE interaction is associated with various mechanisms involved in AD pathology (as discussed above). Where there is evidence to suggest that multiple outcomes may be influenced by PA and APOE in a bi-directional or synergistic manner, they have been included in the same model (see Fig. 4). This narrative also emphasizes the speculative associations that remain to be fully elucidated, providing testable hypotheses for future studies (see Table 1).

Table 1

Suggestions for prospective studies. Abbreviations: Aβ (amyloid-beta); *APOE* (apolipoprotein E - gene); ApoE (apolipoprotein E – protein); BBB (brain blood barrier); CNS (central nervous system); PA (physical activity); p-tau (phosphorylated tau) and TLR (toll-like receptor).
Identified testable hypotheses
1. In APOE ε4 carriers, PA, via downregulation of pro-inflammatory cytokines and preservation of the BBB, will reduce the negative effects of pro-inflammatory molecules on Aβ burden. 2. In APOE ε4 carriers, PA, via downregulation of pro-inflammatory cytokines and preservation of the BBB, will reduce the negative effects of pro-inflammatory molecules on tau hyperphosphorylation. 3. PA-induced Aβ clearance by means of protease upregulation will be more efficient in APOE ε4 non-carriers. 4. Immunosenesce and age-related downregulation of neurotrophic factors reduce the ability of PA to counteract the detrimental effects of APOE ε4 carriage. 5. PA will less efficiently contribute to the preservation of capillary pericytes, small vessels and the BBB in the presence of the APOE ε4 allele. 6. Alternatively, greater levels of PA might be required for APOE ε4 carriers to show improvements in the integrity of the BBB. 7. PA will improve insulin signaling and glucose metabolism in the CNS even in the presence of the APOE ε4 allele. 8. Midlife PA will reduce the risk of brain insulin resistance in late life, even in the presence of the APOE ε4 allele.
Relevant exploratory questions
1. Can PA counteract the increased Aβ oligomerization driven by ApoE4 presence? 2. Does PA, through increased expression of neurotrophic factors, still promote neurogenesis and synaptogenesis despite the detrimental effects of APOE ε4 carriage on lipid transport? 3. How does APOE genotype modulate the neurotrophic response to PA in clinical subgroups at various stages of disease progression? 4. Does PA improve glucose metabolism, glucose transporters levels, insulin receptor and transporters levels and mitochondrial function in the presence of the APOE ε4 allele? 5. Can PA revert brain insulin signaling and glucose metabolism impairments regardless of APOE genotype?

Aβ oligomers neurotoxicity and aggregation is the most studied marker of AD, and both PA and APOE ε4 carriage influence Aβ production and clearance in opposing directions. In fact, ε4 carriers might benefit the most from PA, at least in terms of reduced Aβ deposition(6). Whether PA also counteracts APOE ε4 carriage (associated to enhanced Aβ oligomerization(9)) in terms of decreased soluble Aβ remains to be understood. This is important, given that it is widely accepted that the neurotoxicity associated to Aβ oligomers rather than Aβ plaques drives most of the detrimental downstream effects leading to AD neuropathology(8). For example, Aβ oligomers have been identified to cause mitochondrial dysfunction, and so does the presence of ApoE4(115). PA seems to improve mitochondrial function(103), but its effects in APOE ε4 carriers remain unknown. Another defining feature of AD is tau pathology, although research on how PA and/or APOE ε4 carriage modulate tau is very scarce. Preventing tau pathology is crucial, since this biomarker is more closely associated with neurodegeneration and cognitive decline than amyloid pathology alone(116, 117). Tau pathology may be exacerbated in ε4 carriers, potentially mediated by the presence of Aβ oligomers(36, 37). In this case, PA, through its positive effects on Aβ (in the presence of the APOE ε4 allele), might prevent increased tau pathology. This hypothesis could be examined by longitudinal examinations of brain Aβ and tau in relation to physical activity levels, with examination of the moderating effects of APOE ε4 allele carriage.

A vast body of evidence shows that basal levels of pro-inflammatory molecules are higher among APOE ε4 carriers(86, 87) and lower in physically active individuals(84). Surprisingly, to the best of our knowledge, the interaction between these two factors regarding inflammation is yet to be investigated. There appears to be a bidirectional relationship between amyloid pathology and pro-inflammatory molecules (both directly influenced by PA and APOE ε4 carriage with opposing effects), in that increased inflammatory cytokines may lead to greater Aβ, but also the neurotoxic environment induced by Aβ may lead to greater inflammation(118–120). Animal models also show that exercise interventions can modulate levels of pro-inflammatory cytokines, which coincides with a reduction in Aβ levels(121, 122). Meanwhile, it remains unclear whether modulating inflammatory markers is a mechanism through which exercise reduces Aβ, or whether exercise influences inflammation and Aβ through independent pathways. In a similar fashion, the release of pro-inflammatory substances has been linked to an increase in tau phosphorylation(35), providing another pathway through which PA could contribute to prevent or ameliorate AD pathology. Therefore, it is fundamental to understand the extent of the ability of PA to regulate the immune response even in the presence of the APOE ε4 allele.

Probably the most investigated mechanism through which PA exerts its beneficial effects on brain health is the up-regulation of neurotrophic factors(53–55), particularly in the hippocampus. These molecules include BDNF, IGF-1, and VEGF, and they promote neurogenesis, synaptogenesis and angiogenesis. The enhancement of neurotrophic response might compensate, at least temporarily, for the detrimental effects of AD pathology on brain structure and function. The expression of these neurotrophic factors seems to be reduced in the presence of the APOE ε4 allele(57, 61, 62); indicating the APOE ε4 allele might moderate the acute neurotrophic response to a bout of PA, a hypothesis that requires further investigation. Still, it appears that in APOE ε4 carriers neurotrophic function (i.e., BDNF and TrkB levels) is partially restored in response to habitual PA (64). Future studies should examine the moderating role of the APOE ε4 allele on the PA-induced changes to other neurotrophins and their impact on AD pathology. For example, it seems plausible that PA-induced VEGF could potentiate neuroprotection and prevent Aβ and p-tau aggregation. Additionally, some of these associations may be bi-directional, as aggregation of Aβ plaques can also down-regulate BDNF and IGF-1 expression(123), although no study to date has investigated these interactions in the context of PA research. There is also evidence that the upregulation of pro-inflammatory cytokines in ε4 carriers may influence neurotrophic expression, specifically VEGF(66). However, there is currently limited evidence that APOE isoform-dependent neurotrophic expression is influenced by inflammatory factors, and further research is required.

Some of the most pernicious outcomes associated with APOE ε4 carriage result from the alteration of lipid transport in the brain, which ultimately deteriorates neural remodeling and repair mechanisms, disrupting neuronal communication(73). Accordingly, it would be beneficial to examine whether neurogenesis and synaptogenesis are negatively affected by the carriage of APOE ε4, even when the neurotrophic response to exercise is preserved. Furthermore, lipid transportation impairment has been associated with greater pro-inflammatory responses, via TLRs activation, which would lead to the cascade of effects explained above(86, 90). Given the fact that PA down-regulates the expression of TLRs(84, 85), increasing habitual PA might be an effective intervention to prevent some of the ε4 carriage-related noxious effects.

ApoE4 is exceedingly detrimental to the integrity of the BBB, which undermines Aβ clearance, making the brain more susceptible to toxins(20, 74, 75). In this case, unfortunately, PA has not been found to show a protective effect on the neurovascular unit in the presence of the APOE ε4 in animal models(79). However, it remains plausible that greater levels of PA are required for ε4 carriers to preserve BBB integrity. Promisingly, human studies show that PA exerts a positive effect on cerebrovascular health in APOE ε4 carriers(82). PA-induced increases in VEGF expression could mediate these beneficial outcomes. Finally, vascular integrity is also compromised when glucose metabolism is impaired(95), and APOE ε4 carriage negatively impacts glucose metabolism in the brain. Conversely, PA improves insulin signaling, glucose transport and glucose metabolism(97, 98). These effects have been mostly observed peripherally, although animal studies provide favorable results within the CNS(101–103). However, the combined effect of PA and APOE ε4 carriage on brain glucose metabolism has not been addressed to date. Still, given that both factors act on the same pathways, PA could become a strategic tool to prevent insulin resistance and vascular dysfunction in ε4 carriers, two features that characterize AD neuropathology.

This theoretical article represents the first attempt to create a comprehensive framework to integrate the complex relationships that occur between APOE ε4 carriage and PA engagement at multiple levels, which ultimately modulate AD risk. From our perspective, at least part of the variability within this field emerges as a result of the usage of different outcome measures to characterize the interaction between these two contributing factors. For instance, as we have reported here, the detrimental effect of APOE ε4 carriage on Aβ pathology seems to be counteracted by PA engagement, at least at the early stages of the disease. However, PA does not seem to be protective enough against the damage APOE ε4 carriage causes to the BBB, which eventually might lead to additional downstream impairments, including an exacerbation of Aβ pathology. AD is a complex disease and the multiple mechanisms involved in AD pathogenesis are interrelated(124–127), where alterations in certain pathways might trigger further disturbances on other pathways. Besides the mechanistic complexity of AD, this disease is also characterized by a prolongated pathological process, which is believed to last up to 50 years from the earliest silent molecular alterations to the patient’s decease. Along the AD continuum certain effects might be non-linear and time dependent. For example, the neurotrophic response to PA may be contingent on the degree of AD-related neuropathology present, particularly as more advanced aggregation of Aβ plaques can independently down-regulate BDNF and IGF expression(123). Due to the nascent stage of this research area, it is not yet possible to form a single evidence-based model which includes all relevant associations between the AD-related outcomes discussed above. Therefore, in addition to our proposed integrative model, we also suggest directions for future research to allow the development of such a comprehensive model (see Table 1).

There are key methodological considerations that should be carefully addressed when designing prospective studies. Firstly, methodological variations in biomarkers assessment hinder comparisons across studies. Moreover, there is currently a critical lack of longitudinal studies examining both PA and APOE genotype looking at the evolution of biomarker levels rather than AD incidence in humans. This obstacle has been partially overcome in animal studies. However, there are important differences in the APOE gene between mice and humans, complicating research on the field(128, 129). Most animal studies have utilized transgenic mice carrying the human APOE ε4 variant, where they often induce the expression of classical AD biomarkers, such as Aβ. Finally, PA levels and exercise routines are often poorly measured and described. More research is needed to establish the PA parameters (i.e., type, volume, intensity and frequency) that maximize beneficial outcomes in at risk populations or at different disease stages.

Through this theoretical article we aim to propose a novel integrative model of how PA and APOE ε4 carriage, independently and in combination, influence the pathogenesis of AD. Looking at the reviewed mechanisms, we identify potential pathways through which the beneficial effects of PA might offset some of the detrimental outcomes of APOE ε4 carriage. Nonetheless, PA does not seem to be able to entirely prevent or revert the noxious effects of genetic risk. This is in line with the idea that PA delays rather than prevents AD neuropathology. Accordingly, the potential of PA to exert its benefits might be dependent on disease stage and the extent of the damage to the above-reviewed mechanisms. Still, given that the molecular alterations associated with AD remain silent for up to 20 years, delays in the onset and progression of neuropathological changes could be clinically meaningful. Moreover, compared to pharmaceutical approaches to AD, which usually tackle one specific pathway, PA influences a wide array of molecular targets that all lie somewhere in the stream of AD risk. Therefore, although PA may not be sufficient to prevent or cure AD, it represents a strong complementary therapeutic tool to be combined with more precise pharmacological interventions.

Aβ

Amyloid-beta AD:Alzheimer’s disease

ABCA1

ATP-binding cassette transporter 1

ADAM-10

A Disintegrin and metalloproteinase domain-containing protein 10

APOE

Apolipoprotein E – gene

ApoE

Apolipoprotein E – protein

APP

Amyloid precursor protein

BACE

β-Site amyloid precursor protein cleaving enzyme 1

BBB

Blood brain barrier

BDNF

Brain-derived neurotrophic factor

CCC

Classical complement cascade

CDK5

Cyclin-dependent kinase 5

CNS

Central nervous system

CSF

Cerebrospinal fluid

GLUT

Glucose transporter

GSK3

Glycogen synthase kinase 3

HDL

High-density lipoproteins

IDE

Insulin-degrading enzyme

IGF

Insulin-like growth factor

Interleukin

ISF

Interstitial fluid

LDL

Low-density lipoprotein

LDLR

LDL receptor

LRP1

LDL receptor–related protein 1

LTP

Long-term potentiation

MCI

Mild Cognitive Impairment

NFT

Neurofibrillary tangle

Nitric oxide

Physical activity

PS1

Presenilin

p-tau

phosphorylated tau

TLR

Toll-like receptor

TNF

Tumor necrosis factor

Targeted replacement

TREM2

Triggering receptor expressed on myeloid cells 2

TrkB

Tropomyosin receptor kinase B

VEGF

Vascular endothelial growth factor

VLDL

Very low-density lipoprotein

VLDLR

VLDL receptor

6.1 Ethics approval and consent to participate

Not applicable.

6.2 Consent for publication

Not applicable.

6.3 Availability of data and materials

Not applicable.

6.4 Competing interests

None of the contributors to this study have any conflict of interest to declare.

6.5 Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

6.6 Authors’ contributions

JF-L and BB outlined the article aims and structure; JF-L, KS; AG-C, and SM conducted a thorough literature search; JF-L drafted sections 1, 2.4, 2.6, 3, 4 and 5. KS drafted sections 2.1 and 2.2.; SM drafted section 2.3; AG-C drafted section 2.5. All authors contributed to design the figures and table, while KS created the figures and JF-L the table. BB and KE revised the original draft and contributed relevant suggestions to the final manuscript. All authors revised and approved the final paper draft.

6.7 Acknowledgements

AGC contribution was supported by a predoctoral scholarship by the Spanish Ministry of Science and Innovation (PRE2019-087612).

American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. 10th ed. Indianapolis: Wolters Kluwer; 2017.
Farrer, Lindsay A, Cupples LA, Haines JL, HYman B, Kukull WA, Mayeux R, et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease. JAMA - J Am Med Assoc. 1997;278(16):22–9.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene Dose of Alipoprotein E Type 4 Allele and the Risk of Alzheimer’s Disease in Late Onset Families. Science (80-) [Internet]. 1993;261:921–3. Available from: www.sciencemag.org
Flowers SA, Rebeck GW. APOE in the normal brain. Neurobiol Dis [Internet]. 2020;136(January). Available from: https://doi.org/10.1016/j.nbd.2019.104724
Smith JC, Nielson K a, Woodard JL, Seidenberg M, Rao SM. Physical activity and brain function in older adults at increased risk for Alzheimer’s disease. Brain Sci. 2013;3(1):54–83.
de Frutos-Lucas J, Frost N, Erickson KI, Serrano JM, Maestu F, Laws SM, et al. Does APOE genotype moderate the relationship between physical activity, brain health and dementia risk? A systematic review. Ageing Res Rev [Internet]. 2020;64. Available from: https://doi.org/10.1016/j.arr.2020.101173
Hardy JA, Higgins GA. Alzheimer’s Disease: The Amyloid Cascade Hypothesis. Science (80-). 1992;256:184–5.
Huang YR, Liu RT. The toxicity and polymorphism of β-amyloid oligomers. Int J Mol Sci. 2020;21(12):1–19.
Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein e, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci. 2012;32(43):15181–92.
Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, et al. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer’s disease. Neurobiol Dis [Internet]. 2016;85:218–24. Available from: http://dx.doi.org/10.1016/j.nbd.2015.11.004
Brown BM, Peiffer J, Rainey-Smith SR. Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. Ageing Res Rev [Internet]. 2019;50:9–18. Available from: https://doi.org/10.1016/j.arr.2019.01.003
Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, et al. Physical activity and risk of cognitive decline: A meta-analysis of prospective studies. J Intern Med. 2011;269(1):107–17.
Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010;12(1):1–12.
Koo JH, Kang EB, Oh YS, Yang DS, Cho JY. Treadmill exercise decreases amyloid-β burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer’s disease. Exp Neurol [Internet]. 2017;288:142–52. Available from: http://dx.doi.org/10.1016/j.expneurol.2016.11.014
Liu H li, Zhao G, Zhang H, Shi L de. Long-term treadmill exercise inhibits the progression of Alzheimer’s disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behav Brain Res [Internet]. 2013;256:261–72. Available from: http://dx.doi.org/10.1016/j.bbr.2013.08.008
Zhang J, Guo Y, Wang Y, Song L, Zhang R, Du Y. Long-term treadmill exercise attenuates Aβ burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer’s disease. Neurosci Lett [Internet]. 2018;666(324):70–7. Available from: https://doi.org/10.1016/j.neulet.2017.12.025
Vasconcelos-Filho FSL, da Rocha Oliveira LC, de Freitas TBC, de Pontes PADS, Rocha-e-Silva RC da, Godinho WDN, et al. Effect of involuntary chronic physical exercise on beta-amyloid protein in experimental models of Alzheimer’s disease: Systematic review and meta-analysis. Exp Gerontol. 2021;153(January).
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol [Internet]. 2019;15(9):501–18. Available from: http://dx.doi.org/10.1038/s41582-019-0228-7
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3(89).
Huynh TP V., Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer’s disease: The influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res [Internet]. 2017;58(5):824–36. Available from: http://dx.doi.org/10.1194/jlr.R075481
Riphagen JM, Ramakers IHGM, Freeze WM, Pagen LHG, Hanseeuw BJ, Verbeek MM, et al. Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer’s pathology. Neurobiol Aging. 2020;85:96–103.
Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002–13.
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19).
Roda AR, Montoliu-Gaya L, Villegas S. The Role of Apolipoprotein e Isoforms in Alzheimer’s Disease. J Alzheimer’s Dis. 2019;68(2):459–71.
Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE Promotes the Proteolytic Degradation of Aβ. Neuron. 2008;58(5):681–93.
He XF, Liu DX, Zhang Q, Liang FY, Dai GY, Zeng JS, et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. Front Mol Neurosci. 2017;10(144).
Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, et al. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer’s disease. Neurobiol Dis [Internet]. 2016;85:218–24. Available from: http://dx.doi.org/10.1016/j.nbd.2015.11.004
Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease. Front Aging Neurosci. 2014;6(MAY):1–12.
Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-ε4 allele. Am J Pathol [Internet]. 2003;162(1):313–9. Available from: http://dx.doi.org/10.1016/S0002-9440(10)63822-9
Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006;65(10):1012–21.
Grundke-Iqbal I, Iqbal K, Tung YC. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–7.
Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau with Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019;76(8):915–24.
Gratuze M, Julien J, Morin F, Marette A, Planel E. Differential effects of voluntary treadmill exercise and caloric restriction on tau pathogenesis in a mouse model of Alzheimer’s disease-like tau pathology fed with Western diet. Prog Neuro-Psychopharmacology Biol Psychiatry [Internet]. 2017;79(August):452–61. Available from: http://dx.doi.org/10.1016/j.pnpbp.2017.08.001
Baker LD, Bayer-Carter JL, Skinner J, Montine TJ, Cholerton BA, Callaghan M, et al. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment. J Alzheimer’s Dis. 2012;28(1):137–46.
Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004;295(1):245–57.
Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without β-amyloid. Neurobiol Aging [Internet]. 2016;37:19–25. Available from: http://dx.doi.org/10.1016/j.neurobiolaging.2015.09.011
Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature [Internet]. 2017;549(7673):523–7. Available from: http://dx.doi.org/10.1038/nature24016
Hou TT, Han YD, Cong L, Liu CC, Liang XY, Xue FZ, et al. Apolipoprotein e Facilitates Amyloid-β Oligomer-Induced Tau Phosphorylation. J Alzheimer’s Dis. 2020;74(2):521–34.
Koch G, Di Lorenzo F, Loizzo S, Motta C, Travaglione S, Baiula M, et al. CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer’s disease. Sci Rep. 2017;7(1):1–12.
Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron [Internet]. 2021;109(15):2413–2426.e7. Available from: http://dx.doi.org/10.1016/j.neuron.2021.05.034
Huang EJ, Reichardt LF. Neurotrophins: Roles in Neuronal Development and Function. Annu Rev Neurosci. 2001;24:677–736.
Allen SJ, Watson JJ, Dawbarn D. The Neurotrophins and Their Role in Alzheimer’s Disease. Curr Neuropharmacol. 2011;9:559–73.
Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A, Science S, Series N, et al. Linked references are available on JSTOR for this article: Postsynaptic Induction of BDNF-Mediated Long-Term Potentiation. Science (80-). 2002;295(5560):1729–34.
Uysal N, Kiray M, Sisman A, Camsari U, Gencoglu C, Baykara B, et al. Effects of voluntary and involuntary exercise on cognitive functions, and VEGF and BDNF levels in adolescent rats Effects of voluntary and involuntary exercise on cognitive functions, and VEGF and BDNF levels. Biotech Histochem. 2015;90(1):55–68.
Carro E, Trejo JL, Busiguina S, Torres-aleman I. Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy. J Neurosci. 2001;21(15):5678–84.
Lange C, Storkebaum E, Almodóvar CR De, Dewerchin M, Carmeliet P. Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol. 2016;
Lopez-LopezD C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. PNAS. 2004;101(26):9833–8.
Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain- derived neurotrophic factor. J Psychiatr Res. 2016;60:56–64.
Marinus N, Hansen D, Feys P, Meesen R, Timmermans A, Spildooren J. The Impact of Different Types of Exercise Training on Peripheral Blood Brain – Derived Neurotrophic Factor Concentrations in Older Adults: A Meta – Analysis. Sport Med [Internet]. 2019; Available from: https://doi.org/10.1007/s40279-019-01148-z
Devenney KE, Guinan EM, Kelly ÁM, Mota BC, Walsh C, Rikkert MO, et al. Acute high-intensity aerobic exercise affects brain-derived neurotrophic factor in mild cognitive impairment: a randomised controlled study. BMJ Open Sport Exerc Med. 2019;5.
Van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005;25(38):8680–5.
Liu PZ, Nusslock R. Exercise-Mediated Neurogenesis in the Hippocampus via BDNF. Front Neurosci. 2018;12(52).
Morland C, Andersson KA, Haugen ØP, Hadzic A, Kleppa L, Gille A, et al. Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nat Commun. 2017;(7491):1–9.
Erickson KI, Voss MW, Shaurya R, Basak C, Szabo A, Chaddock L, et al. Exercise training increases size of hippocampus and improves memory. PNAS. 2011;108(7):3017–22.
Cassilhas RC, Viana VAR, Grassmann V, Santos RT, Santos RF, Tufik S, et al. The Impact of Resistance Exercise on the Cognitive Function of the Elderly. Med Sci Sports Exerc. 2007;39(8):1401–7.
Cassilhas RC, Lee KS, Fernandes J, Oliveira MGM, Tufik S, Meeusen R, et al. Spatial memory is improved by aerobic and resistance exercise through divergent molecular mechhanisms. Neuroscience [Internet]. 2012;202:309–17. Available from: http://dx.doi.org/10.1016/j.neuroscience.2011.11.029
Liu Y, Jiao S, Wang Y, Bu X, Yao X, Xiang Y, et al. Associations Between ApoE ε 4 Carrier Status and Serum BDNF Levels — New Insights into the Molecular Mechanism of ApoE ε 4 Actions in Alzheimer ’ s Disease. Mol Neurobiol. 2015;51:1271–7.
Alvarez A, Aleixandre M, Linares C, Masliah E, Moessler H. Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer’s disease. J Alzheimer’s Dis. 2016;42(4):1347–55.
Zheng L, Kong X, Cui Y, Wei Y, Zhang J, Wei W. Neuroscience Letters Conversion from MCI to AD in patients with the APOE E4 genotype: Prediction by plasma HCY and serum BDNF. Neurosci Lett [Internet]. 2016;626:19–24. Available from: http://dx.doi.org/10.1016/j.neulet.2016.05.018
Sen A, Nelson TJ, Alkon DL. ApoE isoforms differentially regulates cleavage and secretion of BDNF. Mol Brain. 2017;10(19):1–7.
Keeney JT-R, Ibrahimi S, Zhao L. Human ApoE isoforms differentially modulate glucose and amyloid metabolic pathways in female brain: evidence of the mechanism of neuroprotection by ApoE2 and implications for Alzheimer’s prevention and early intervention. J Alzheimer’s Dis. 2015;48(2):411–424.
Salomon-zimri S, Glat MJ, Barhum Y, Luz I. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment. J Alzheimer’s Dis. 2016;53:1443–1458.
Zhao J, Davis MD, Martens YA, Shinohara M, Graff-radford NR, Younkin SG, et al. APOE e4/e4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26(14):2690–700.
Nichol K, Deeny SP, Seif J, Camaclang K, Cotman CW. Exercise improves cognition and hippocampal plasticity in APOE e4 mice. Alzheimer’s Dement. 2009;5:287–94.
Levi O, Michaelson DM. Environmental enrichment stimulates neurogenesis in apolipoprotein E3 and neuronal apoptosis in apolipoprotein E4 transgenic mice. J Neurochem. 2007;100:202–10.
Moore AM, Mahoney E, Dumitrescu L, Jager PL De, Ellen M, Koran I, et al. Neurobiology of Aging APOE ε 4-speci fi c associations of VEGF gene family expression with cognitive aging and Alzheimer ’ s disease. Neurobiol Aging [Internet]. 2020;87:18–25. Available from: https://doi.org/10.1016/j.neurobiolaging.2019.10.021
Maass A, Düzel S, Goerke M, Becke A, Sobieray U, Neumann K, et al. Vascular hippocampal plasticity after aerobic exercise in older adults. Mol Psychiatry. 2015;20(5):585–93.
Kennedy G, Hardman RJ, Macpherson H, Scholey AB, Pipingas A. How Does Exercise Reduce the Rate of Age-Associated Cognitive Decline ? A Review of Potential Mechanisms. J Alzheimer’s Dis. 2017;55:1–18.
Intzandt B, Sabra D, Foster C, Desjardins-Crépeau L, Hoge RD, Steele CJ, et al. Higher cardiovascular fitness level is associated with lower cerebrovascular reactivity and perfusion in healthy older adults. J Cereb Blood Flow Metab. 2019;0(0):1–14.
Ross MD, Malone E, Florida-James G. Vascular Ageing and Exercise: Focus on Cellular Reparative Processes. Oxid Med Cell Longev. 2016;2016:18–20.
Altman R, Rutledge JC. The vascular contribution to Alzheimer’s disease. Clin Sci. 2010;119(10):407–21.
Fernandez CG, Hamby ME, McReynolds ML, Ray WJ. The role of apoE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer’s disease. Front Aging Neurosci. 2019;10(FEB):1–18.
Chew H, Solomon VA, Fonteh AN. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. Front Physiol. 2020;11(June):1–28.
Chernick D, Ortiz-Valle S, Jeong A, Qu W, Li L. Peripheral Versus Central Nervous System APOE in Alzheimer’s Disease: Interplay across the Blood-Brain Barrier. Neurosci Lett. 2019;708.
Govindpani K, McNamara LG, Smith NR, Vinnakota C, Waldvogel HJ, Faull RLM, et al. Vascular dysfunction in Alzheimer’s disease: A prelude to the pathological process or a consequence of it? J Clin Med. 2019;8(5):1–57.
Leon M Tai, Thomas R, Marottoli FM, Koster KP, Kanekiyo T, Morris AW, et al. The Role of APOE in Cerebrovascular Dysfunction Leon. Acta Neuropathol. 2016;131(5):709–723.
Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to early blood-brain barrier dysfunction predicting human cognitive decline. Vol. 581, Nature. 2020. 71–76 p.
Brandon JA, Farmer BC, Williams HC, Johnson LA. APOE and alzheimer’s disease: Neuroimaging of metabolic and cerebrovascular dysfunction. Front Aging Neurosci. 2018;10(180).
Soto I, Graham LC, Richter HJ, Simeone SN, Radell JE, Grabowska W, et al. APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction. PLoS Biol. 2015;13(10):1–33.
Di Cataldo V, Géloën A, Langlois JB, Chauveau F, Thézé B, Hubert V, et al. Exercise does not protect against peripheral and central effects of a high cholesterol diet given ad libitum in old ApoE-/- mice. Front Physiol. 2016;7(OCT):1–12.
Hansson O, Svensson M, Gustaysson A-M, Andersson E, Yang Y, Nagga K, et al. Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease. Alzheimer’s Res Ther. 2019 Oct;11(87).
Zlatar ZZ, Wierenga CE, Bangen KJ, Liu TT, Jak AJ. Increased hippocampal blood flow in sedentary older adults at genetic risk for Alzheimer’s disease. J Alzheimer’s Dis. 2014;41(3):809–17.
Phillips C, Baktir MA, Srivatsan M, Salehi A. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci [Internet]. 2014;8(June):1–16. Available from: http://journal.frontiersin.org/article/10.3389/fncel.2014.00170/abstract
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol [Internet]. 2011;11(9):607–10. Available from: http://dx.doi.org/10.1038/nri3041
Weyh C, Krüger K, Strasser B. Physical activity and diet shape the immune system during aging. Nutrients. 2020;12(3):1–17.
Gale SC, Gao L, Mikacenic C, Coyle SM, Rafaels N, Murray Dudenkov T, et al. APOε4 is associated with enhanced in vivo innate immune responses in humans. J Allergy Clin Immunol. 2014;134(1):127–34.
Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30(9):1350–60.
Wong MY, Lewis M, Doherty JJ, Shi Y, Cashikar AG, Amelianchik A, et al. 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. J Neuroinflammation. 2020;17(192).
Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai L, Yu C, Rebeck GW, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia [Internet]. 2012;60(4):559–569. Available from: file:///C:/Users/ASUS/Desktop/Rujukan PhD/Dev of drug R cell line/nihms579608.pdf
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer’s disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759–772.
Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019;25(3):496–506.
Leckie RL, Weinstein AM, Hodzic JC, Erickson KI. Potential moderators of physical activity on brain health. J Aging Res. 2012;
Tokgöz S, Claassen JAHR. Exercise as Potential Therapeutic Target to Modulate Alzheimer’s Disease Pathology in APOE ε4 Carriers: A Systematic Review. Cardiol Ther. 2021;10(1):67–88.
de la Monte SM, Wand JR. Alzheimer ’ s Disease Is Type 3 Diabetes — Evidence Reviewed. J Diabetes Sci Technol. 2008;2(6):1954–60.
Bridget M, Kuehn MSJ. In Alzheimer Research, Glucose Metabolism Moves to Center Stage. JAMA - J Am Med Assoc. 2020;323(4):297–9.
McIntosh EC, Nation DA. Importance of treatment status in links between type 2 diabetes and Alzheimer’s disease. Diabetes Care. 2019;42(5):972–9.
Borghouts LB, Keizer HA. Exercise and insulin sensitivity: A review. Int J Sports Med. 1999;20.
Yaribeygi H, Atkin SL, Simental-Mendía LE, Sahebkar A. Molecular mechanisms by which aerobic exercise induces insulin sensitivity. J Cell Physiol. 2019;
Kumar SA, Maiya AG, Shastry BA, Vaishali K, Ravishankar N, Hazari A, et al. Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis. Ann Phys Rehabil Med [Internet]. 2019;62(2):98–103. Available from: https://doi.org/10.1016/j.rehab.2018.11.001
Gaitán JM, Boots EA, Dougherty RJ, Oh JM, Ma Y, Edwards DF, et al. Brain Glucose Metabolism, Cognition, and Cardiorespiratory Fitness Following Exercise Training in Adults at Risk for Alzheimer’s Disease. Brain Plast. 2019;5:83–95.
Chirico EN, Di Cataldo V, Chauveau F, Geloën A, Patsouris D, Thézé B, et al. Magnetic resonance imaging biomarkers of exercise-induced improvement of oxidative stress and inflammation in the brain of old high-fat-fed ApoE–/– mice. J Physiol. 2016;594(23):6969–85.
Park HS, Park SS, Kim CJ, Kim TW, Kim TW. Exercise alleviates cognitive functions by enhancing hippocampal insulin signaling and neuroplasticity in high-fat diet-induced obesity. Nutrients. 2019;11(7).
Park HS, Cho HS, Kim TW. Physical exercise promotes memory capability by enhancing hippocampal mitochondrial functions and inhibiting apoptosis in obesity-induced insulin resistance by high fat diet. Metab Brain Dis. 2018;33:283–92.
Zhao N, Liu C, Ingelgom AJ Van, Martens YA, Knight JA, Painter MM, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron. 2017;96(1):115–29.
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer’s Dis. 2008;13:323–31.
Mosconi L, Nacmias B, Sorbi S, De Cristofaro MTR, Fayazz M, Tedde A, et al. Brain metabolic decreases related to the close of the ApoE e4 allele in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75(3):370–6.
Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology. 2005;64(1):102–7.
Ossenkoppele R, Van Der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 2013;80(4):359–65.
Krell-Roesch J, Syrjanen JA, Vassilaki M, Lowe VJ, Vemuri P, Mielke MM, et al. Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. Am J Geriatr Psychiatry [Internet]. 2021;29(2):179–91. Available from: https://doi.org/10.1016/j.jagp.2020.06.006
Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R, et al. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. NeuroImage Clin. 2019;22(March).
An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, et al. Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimer’s Dement. 2018;14(3):318–29.
Chan ES, Chen C, Soong TW, Wong BS. Differential Binding of Human ApoE Isoforms to Insulin Receptor is Associated with Aberrant Insulin Signaling in AD Brain Samples. NeuroMolecular Med [Internet]. 2018;20:124–32. Available from: https://doi.org/10.1007/s12017-018-8480-3
Wu L, Zhang X, Zhao L. Human apoe isoforms differentially modulate brain glucose and ketone body metabolism: Implications for Alzheimer’s disease risk reduction and early intervention. J Neurosci. 2018;38(30):6665–81.
Zhang X, Wu L, Zhao L. Neuroscience 2019. Session 651 - Alzheimer’s Disease: Energy Homeostasis. In: Poster ApoE2-mediated neuroprotective mechanism through regulation of glycolysis. 2019. p. 651.06 / C78.
Dose J, Huebbe P, Nebel A, Rimbach G. APOE genotype and stress response - A mini review. Lipids Health Dis [Internet]. 2016;15(121):1–15. Available from: http://dx.doi.org/10.1186/s12944-016-0288-2
Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer’s Dement [Internet]. 2020;1–8. Available from: https://doi.org/10.1016/j.jalz.2019.09.075
Kametani F, Hasegawa M. Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer ’ s Disease. Front Neurosci. 2018;12.
Ambrée O, Leimer U, Herring A, Görtz N, Sachser N, Heneka MT, et al. Reduction of amyloid angiopathy and Aβ plaque burden after enriched housing in TgCRND8 mice: Involvement of multiple pathways. Am J Pathol. 2006;169(2):544–52.
Philippens IH, Ormel PR, Baarends G, Johansson M, Remarque EJ. Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer ’ s Disease. J Alzeimer’s Dis. 2017;55:101–13.
Tejera D, Mercan D, Sanchez-caro JM, Hanan M, Greenberg D, Soreq H, et al. Systemic inflammation impairs microglial A b clearance through NLRP 3 inflammasome. EMBO J. 2019;38.
Hashiguchi D, Correia H, Wuo-silva R, Faber J, Monteiro B. Resistance Exercise Decreases Amyloid Load and Modulates Inflammatory Responses in the APP / PS1 Mouse Model for Alzheimer ’ s Disease. 2020;73:1525–39.
Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation. 2008;40:1–15.
Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer ’ s Disease. J Neurosci. 2009;29(29):9321–9.
Luo J, Wärmländer SKTS, Gräslund A, Abrahams JP. Reciprocal Molecular Interactions between the Aβ Peptide Linked to Alzheimer’s Disease and Insulin Linked to Diabetes Mellitus Type II. ACS Chem Neurosci. 2016;7(3):269–74.
Tofoleanu F, Buchete NV. Molecular interactions of Alzheimer’s Aβ protofilaments with lipid membranes. J Mol Biol [Internet]. 2012;421(4–5):572–86. Available from: http://dx.doi.org/10.1016/j.jmb.2011.12.063
Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19(R1):12–20.
Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell [Internet]. 2019;179(2):312–39. Available from: https://doi.org/10.1016/j.cell.2019.09.001
Balu D, Karstens AJ, Loukenas E, Maldonado Weng J, York JM, Valencia-Olvera AC, et al. The role of APOE in transgenic mouse models of AD. Neurosci Lett [Internet]. 2019;707(January):134285. Available from: https://doi.org/10.1016/j.neulet.2019.134285
Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: Limitation of mouse APOE model in studying Alzheimer’s disease. J Neurochem. 2007;103(3):1237–57.

No competing interests reported.

Download PDF

Journal Publication

published 27 Jan, 2023

Read the published version in Alzheimer's Research & Therapy →

Editorial decision: Major revision
28 Oct, 2022
Reviews received at journal
27 Oct, 2022
Reviewers agreed at journal
08 Oct, 2022
Reviewers invited by journal
15 Jun, 2022
Submission checks completed at journal
15 Jun, 2022
Editor assigned by journal
15 Jun, 2022
First submitted to journal
13 Jun, 2022

You are reading this latest preprint version

How does Apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model

Status:

Journal Publication

Version 1

Abstract

Figures

Key Points

1. Background And Objective

2. How Do Genotype And Physical Activity Influence Alzheimer’s Neuropathology?

2.1. Amyloid pathology

2.2. Tau pathology

2.3. Neurotrophic factors

2.4. Cerebrovascular alterations

2.5. Neuroimmune response

2.6. Brain glucose metabolism

3. The Combined Effect Of Physical Activity And Apoe ε4 Carriage On Ad-related Mechanisms: An Integrative Model Proposal.

4. Major Challenges

5. Conclusions

Abbreviations

Declarations

6.1 Ethics approval and consent to participate

6.2 Consent for publication

6.3 Availability of data and materials

6.4 Competing interests

6.5 Funding

6.6 Authors’ contributions

6.7 Acknowledgements

References

Additional Declarations

Status:

Journal Publication

Version 1